Print this page for your doctor
CLINICAL TRIAL SUMMARY
MDACC Study No:
(clinicaltrials.gov NCT No:
Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes
The goal of this clinical research study is to compare the effects of
ruxolitinib against those of hydroxyurea in patients with polycythemia vera
(PV). The safety of these drugs will also be studied.
Ruxolitinib is designed to block a gene mutation that may be important in
cancer cell growth and survival. This may cause the cancer cells to die.
Hydroxyurea is designed to block cancer cells from dividing. This may cause
the cancer cells to die.
In this study, both drugs are being compared to placebos. A placebo is not a
drug. It looks like the study drug but is not designed to treat any disease or
illness. It is designed to be compared with a study drug to learn if the study
drug has any real effect.
Phase of Study:
Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Study Contact Information
For Clinical Trial Enrollment:
For General Questions about Clinical Trials:
800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)
Study Objectives / Outcomes
Study Status Information
Resources and Links
Return to List